NeoGenomics (NEO) Stock Forecast & Price Target

Compare

1,878 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NEO Analyst Ratings

Moderate Buy

4 Buy

7 Hold

0 Sell

Based on 11 analysts giving stock ratings to

NeoGenomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NEO Stock 12 Month Forecast

Average Price Target

$9.29

▲(65.30% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $9.29 with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 65.30% change from the last price of $5.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","19":"$19","7.75":"$7.75","11.5":"$11.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.75,11.5,15.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.686153846153847,6.212307692307693,6.7384615384615385,7.264615384615385,7.790769230769231,8.316923076923077,8.843076923076923,9.36923076923077,9.895384615384616,10.421538461538463,10.947692307692307,11.473846153846154,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.477692307692307,5.795384615384616,6.113076923076923,6.430769230769231,6.748461538461538,7.066153846153846,7.383846153846154,7.701538461538461,8.019230769230768,8.336923076923076,8.654615384615383,8.972307692307691,{"y":9.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.378461538461538,5.596923076923077,5.815384615384615,6.033846153846154,6.252307692307692,6.470769230769231,6.689230769230769,6.907692307692308,7.126153846153846,7.344615384615384,7.563076923076923,7.781538461538462,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.93,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$9.29

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

-2.14%

Downside

Reiterated

08/05/25

The overall stock score reflects NeoGenomics' revenue growth and strategic board appointment but is heavily weighed down by ongoing profitability and cash flow issues, technical bearish signals, and valuation concerns.

David WestenbergPiper Sandler

Piper Sandler

$12→$11

Buy

95.73%

Upside

Reiterated

08/04/25

NeoGenomics (NEO) Gets a Buy from Piper Sandler

Daniel BrennanTD Cowen

TD Cowen

$12→$10

Buy

77.94%

Upside

Reiterated

07/30/25

NeoGenomics: Potential Upside Amidst Challenges and Low Valuation

William BonelloCraig-Hallum

Craig-Hallum

$12

Buy

113.52%

Upside

Reiterated

07/30/25

NeoGenomics (NEO) Receives a Buy from Craig-Hallum

Andrew BrackmannWilliam Blair

William Blair

―

Hold

―

Downgraded

07/30/25

NeoGenomics (NEO) was downgraded to a Hold Rating at William BlairWe actually think this could be a “monster” of a stock in 2026 if the company executes and builds trust—both of which could drive multiple expansion. But for now, having seen what and how long it can take for momentum to turn around in this sector, we downgrade.

Mark MassaroBTIG

BTIG

―

Hold

―

Downgraded

07/30/25

NeoGenomics (NEO) was downgraded to a Hold Rating at BTIG

Bruce JacksonBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

07/30/25

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NASDAQ: NEO) and TNL Mediagene (NASDAQ: TNMG)so we are maintaining our Hold rating

Yuko OkuMorgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

42.35%

Upside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Michael MatsonNeedham

Needham

Buy

42.35%

Upside

Reiterated

07/29/25

NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges

Puneet SoudaLeerink Partners

Leerink Partners

Hold

42.35%

Upside

Reiterated

07/29/25

NeoGenomics Faces Revenue Guidance Cut and Growth Challenges, Analyst Maintains Hold RatingWe remained Market Perform, as we wait to see stabilization of the business before becoming more constructive. We lower our price target from $9 to $8 (1.0x FY26 revs multiple).

Michael RyskinBank of America Securities

Bank of America Securities

$10→$8

Hold

42.35%

Upside

Reiterated

07/18/25

Bank of America Securities Sticks to Their Hold Rating for NeoGenomics (NEO)

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Initiated

05/15/25

NeoGenomics initiated with a Neutral at GuggenheimNeoGenomics initiated with a Neutral at Guggenheim

Matthew SykesGoldman Sachs

Goldman Sachs

$17→$15

Buy

166.90%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Unknown AnalystTD Securities

Not Ranked

TD Securities

$20→$19

Buy

238.08%

Upside

Reiterated

02/19/25

Lowering PT to $19 from $20.

Tycho PetersonJefferies

Jefferies

$22→$18

Buy

220.28%

Upside

Reiterated

02/18/25

Neogenomics (NEO) PT Lowered to $18 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

-2.14%

Downside

Reiterated

08/05/25

David WestenbergPiper Sandler

Piper Sandler

$12→$11

Buy

95.73%

Upside

Reiterated

08/04/25

NeoGenomics (NEO) Gets a Buy from Piper Sandler

Daniel BrennanTD Cowen

TD Cowen

$12→$10

Buy

77.94%

Upside

Reiterated

07/30/25

NeoGenomics: Potential Upside Amidst Challenges and Low Valuation

William BonelloCraig-Hallum

Craig-Hallum

$12

Buy

113.52%

Upside

Reiterated

07/30/25

NeoGenomics (NEO) Receives a Buy from Craig-Hallum

Andrew BrackmannWilliam Blair

William Blair

―

Hold

―

Downgraded

07/30/25

Mark MassaroBTIG

BTIG

―

Hold

―

Downgraded

07/30/25

NeoGenomics (NEO) was downgraded to a Hold Rating at BTIG

Bruce JacksonBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

07/30/25

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NASDAQ: NEO) and TNL Mediagene (NASDAQ: TNMG)so we are maintaining our Hold rating

Yuko OkuMorgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

42.35%

Upside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Michael MatsonNeedham

Needham

Buy

42.35%

Upside

Reiterated

07/29/25

NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges

Puneet SoudaLeerink Partners

Leerink Partners

Hold

42.35%

Upside

Reiterated

07/29/25

Michael RyskinBank of America Securities

Bank of America Securities

$10→$8

Hold

42.35%

Upside

Reiterated

07/18/25

Bank of America Securities Sticks to Their Hold Rating for NeoGenomics (NEO)

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Initiated

05/15/25

NeoGenomics initiated with a Neutral at GuggenheimNeoGenomics initiated with a Neutral at Guggenheim

Matthew SykesGoldman Sachs

Goldman Sachs

$17→$15

Buy

166.90%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Unknown AnalystTD Securities

Not Ranked

TD Securities

$20→$19

Buy

238.08%

Upside

Reiterated

02/19/25

Lowering PT to $19 from $20.

Tycho PetersonJefferies

Jefferies

$22→$18

Buy

220.28%

Upside

Reiterated

02/18/25

Neogenomics (NEO) PT Lowered to $18 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeoGenomics

1 Month

xxx

Success Rate

7/15 ratings generated profit

Average Return

-0.99%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of -0.99% per trade.

3 Months

xxx

Success Rate

6/17 ratings generated profit

Average Return

-6.20%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.29% of your transactions generating a profit, with an average return of -6.20% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

6/15 ratings generated profit

Average Return

-19.05%

reiterated a buy rating 9 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -19.05% per trade.

2 Years

xxx

Success Rate

3/15 ratings generated profit

Average Return

-35.01%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -35.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NEO Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NEO has received 5 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. NEO average Analyst price target in the past 3 months is 9.29.

Each month's total comprises the sum of three months' worth of ratings.

NEO Financial Forecast

NEO Earnings Forecast

Next quarter’s earnings estimate for NEO is $0.02 with a range of -$0.02 to $0.05. The previous quarter’s EPS was $0.03. NEO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year NEO has Preformed in-line its overall industry.

NEO Sales Forecast

Next quarter’s sales forecast for NEO is $183.77M with a range of $181.40M to $185.33M. The previous quarter’s sales results were $181.33M. NEO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year NEO has Preformed in-line its overall industry.

NEO Stock Forecast FAQ

What is NEO’s average 12-month price target, according to analysts?

Based on analyst ratings, NeoGenomics Inc.’s 12-month average price target is 9.29.

What is NEO’s upside potential, based on the analysts’ average price target?

NeoGenomics Inc. has 65.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NEO a Buy, Sell or Hold?

NeoGenomics Inc. has a consensus rating of Moderate Buy which is based on 4 buy ratings, 7 hold ratings and 0 sell ratings.

What is NeoGenomics Inc.’s price target?

The average price target for NeoGenomics Inc. is 9.29. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $8.00. The average price target represents 65.30% Increase from the current price of $5.62.

What do analysts say about NeoGenomics Inc.?

NeoGenomics Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of NEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NeoGenomics (NEO) Stock Forecast & Price Target

NEO Analyst Ratings

NEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeoGenomics

NEO Analyst Recommendation Trends

NEO Financial Forecast

NEO Earnings Forecast

NEO Sales Forecast

NEO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts